Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sarepta licenses Summit’s DMD drugs
by Lisa M. Jarvis
October 10, 2016
| A version of this story appeared in
Volume 94, Issue 40
In its second partnership since FDA approval last month of eteplirsen, its exon-skipping Duchenne muscular dystrophy treatment, Sarepta Therapeutics has licensed the European rights to Summit Therapeutics’ utrophin modulator pipeline. The deal includes ezutromid, which is in a Phase II study for treating DMD. Summit will get $40 million up front and could reap another $522 million in milestone payments. Late last month, Sarepta teamed with Catabasis to study combining its exon-skipping drugs with Catabasis’s NF-κB inhibitors.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter